December 03, 2019

Published: December 03, 2019
Category:
Britton Smith Foundation Clinical Trials Fund

At the Canadian Cancer Society, our vision to create a world in which no Canadian fears cancer is only achievable if we work collectively with people united by the same goals. With nearly one in two Canadians expected to be diagnosed with cancer in their lifetime, cancer affects us all.

At the cancer society, we believe research is the best way to accelerate progress so that more cancers can be prevented, and more people will not just survive cancer, but live longer and fuller lives.

Today more than 60 per cent of Canadians diagnosed with cancer will survive, compared with about 25 per cent in the 1940s, because of the advancements discovered through research. We are determined to empower people with cancer and ensure there are new treatment options for Canadians. One way we do this is through our support of life-saving clinical trials.

A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office

 

Read More

November 27, 2019

Published: November 27, 2019
Category: Trials
Trial Closure: IND208, IND221, IND229, ES2

The following CCTG trials have been permanently closed.

Read More

Published: November 27, 2019
Category: Group updates

We are coming up to a big holiday for American families. Please expect closure of U.S. Operations offices and laboratories on Thursday, November 28nd for the U.S. Thanksgiving. If you are planning to ship specimens to the U.S., please plan accordingly. Also remember that many of our U.S. collegues take additional holidays for an extra long weekend.

Happy Thanksgiviing to our U.S friends!

Read More

Published: November 27, 2019
Category: News
 Dr. Kuruvilla and Dr. Crump about CCTG LY17

CCTG LY17 is a A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma. The trial is looking to determine the overall response rate (complete and partial response) to novel combination therapy in patients with relapsed and refractory aggressive B cell lymphoma. Dr. Kuruvilla and Dr. Crump stress the importance of this trial, collaboration within CCTG, and the overall benefit of cancer clinical trials. (NCT02436707)

Read More

Published: November 27, 2019
Category: News
Congratulations to Dr. Sarit Assouline

CCTG is pleased to announce that the fall recipient of the Frances A. Shepherd Award is Dr. Assouline Division of Hematology McGill University, Jewish General Hospital Montreal, Quebec and the CCTG Hematologic Disease Site Chair

Read More

Published: November 27, 2019
Category: Publications

Citations which reference published CCTG trials for MAC12, MA27 and MAC1

Read More

Published: November 27, 2019
Category: Publications
Publication - IND229 and IND222

IND229 Publication: A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2 - Positive Metastatic Breast Cancer

IND222 Publication: A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: A CCTG study.

Read More

November 13, 2019

Published: November 13, 2019
Category: Trials
Trial Activation: ENC1

The CCTG ENC1 study, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC#776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer, has been centrally activated and open to accrual.

Read More